Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

Name: Recombinant Human VEGFR2/KDR kinase domain His Protein, CF
Brand: R&D Systems
SKU: 11740-KD

R&D Systems, part of Bio-Techne | Catalog # 11740-KD

Submit a review

Product Datasheet / COA / SDS

His-tag

Key Product Details

Source:	Sf 21 (baculovirus)
Applications:	Enzyme Activity

View Full Technical Details for Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

Technical Data
Citations / Reviews

Product Specifications for Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived human VEGFR2/KDR/Flk-1 protein

Met

6-His tag

Sumo-tag
(mutated, uncleavable)

3c Protease site

Human VEGFR2
(Ala792-Val1356)
Accession # P35968.2

Purity

>85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining

Endotoxin level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal sequence Analysis

Protein identity confirmed by mass spectrometry.

Predicted Molecular Mass

76 kDa

SDS-PAGE

76 kDa

Activity

Measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to a synthetic peptide substrate.

The specific activity is >225 pmol/min/μg, as measured under the described conditions.

Scientific Data Examples for Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

	Recombinant Human VEGFR2/KDR/Flk-1 kinase domain His-tag Enzyme Activity. Recombinant Human VEGFR2/KDR/Flk-1 kinase domain His-tag (Catalog # 11740-KD) is measured by its ability to transfer phosphate from adenosine triphosphate (ATP) to a synthetic peptide substrate.
	Recombinant Human VEGFR2/KDR/Flk-1 kinase domain His-tag SDS-PAGE. 2 μg/lane of Recombinant Human VEGFR2/KDR/Flk-1 kinase domain His-tag (Catalog # 11740-KD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 87-101 kDa, under reducing conditions.

Formulation, Preparation and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11740-KD

Formulation	Supplied as a 0.2 μm filtered solution in Tris, NaCl, DTT and Glycerol.
Shipping	The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 3 months, -20 to -70 °C under sterile conditions after opening.

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: VEGFR2/KDR/Flk-1

Vascular endothelial growth factor receptor 2 (VEGFR2), also known as Fetal liver kinase 1 (FLK-1) and Kinase insert domain receptor (KDR), is one of three ubiquitously expressed, highly conserved tyrosine protein kinase VEGFRs from the platelet-derived growth factor receptor (PDGFR) family (1). VEGFR2, like other receptor members in this family is comprised of an extracellular domain (ECD) with immunoglobulin-like segments that binds its target cytokine VEGF to induce dimerization, a transmembrane domain, and a cytosolic kinase domain (1). Similar to the structure of other tyrosine kinases, the kinase domain contains the conserved catalytic domain with an ATP binding site within the cleft of two lobes at the N-terminal and C-terminal regions as well as the glycine-rich or nucleotide binding loop and activation loop (1,2). Unique to this family there is also a kinase insert domain (KID) of unknown function (1). Through ligand binding, dimerization, activation via autophosphorylation, and subsequent phosphorylation of targets in multiple signaling pathways, VEGFR2 regulates endothelial cell growth, migration, and survival and plays a critical role in angiogenesis (2-4). Abnormal angiogenesis is a hallmark of tumor progression and metastasis; VEGFR-2 has been reported to be overexpressed and overstimulated in tumors and thus closely linked to the occurrence and development of multiple types of tumors (2,5,6). Targeting inhibition of VEGFR2 is a promising cancer therapeutic strategy based on multiple clinical trials (2,4,7). There is significant research and interest in the development of drugs targeting VEGFR2 inhibition (8) especially including dual inhibition in combination with other kinases or other proteins (9-15).

Item	Value
References	McTigue, M.A. et al. (1999) Structure 7:319. Liu, Y. et al. (2022) J. Hematol. Oncol. 15:89. Simons, M. et al. (2016) Nat. Rev. Mol. Cell Biol. 17:611. Yang, J. et al. (2018) Front. Immunol. 9:978. Zhao, J. et al. (2021) Drug Target. 29:155. Prasad, C.B. et al. (2022) Int. J. Biochem. Cell Biol. 142:106122. Zhu, P. et al. (2017) Onco. Targ. Ther. 10:4315. Shi, L. et al. (2016) Curr. Med. Chem. 23:1000. Chekler, E.L. et al. (2010) ACS Med. Chem. Lett. 1:488. Tang, Z. et al. (2016) Eur. J. Med. Chem. 118:328. Brands, R.C. et al. (2017) Oncol. Rep. 38:1877. Abdel-Mohsen, H.T. et al. (2019) Eur. J. Med. Chem. 179:707. Carvalho, B. et al. (2021) Sci. Rep. 11:6067. Abd El-Meguid, E.A. et al. (2022) Bioorg. Med. Chem. Lett. 58:128529. Xue, X. et al. (2022) Invest. New Drugs. 40:10.
Long Name	Vascular Endothelial Growth Factor Receptor 2
Entrez Gene IDs	3791 (Human); 16542 (Mouse)
Alternate Names	CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, FLK1tyrosine kinase growth factor receptor, Fetal liver kinase 1, Flk-1, Flk1, KDR, KRD1, Kinase insert domain receptor, Ly73, Protein-tyrosine kinase receptor flk-1, VEGF R2, VEGFR, VEGFR-2, VEGFR2, fetal liver kinase-1, kinase insert domain receptor (a type III receptor tyrosine kinase), soluble VEGFR2, vascular endothelial growth factor receptor 2

Customer Reviews for Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human VEGFR2/KDR kinase domain His Protein, CF and earn rewards!

Have you used Recombinant Human VEGFR2/KDR kinase domain His Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review

Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11740-KD

Key Product Details

Product Specifications for Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

Scientific Data Examples for Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

Formulation, Preparation and Storage

Carrier Free

Reconstitution Calculator

Background: VEGFR2/KDR/Flk-1

Customer Reviews for Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

Product Documents for Recombinant Human VEGFR2/KDR kinase domain His Protein, CF

Product Datasheets

COA

Certificate of Analysis

SDS

CONTACT INFORMATION

保持关注